Vx-11e

ERK1-2 inhibitor

Also Known As:

1H-Pyrrole-2-carboxamide, 4-(2-((2-chloro-4-fluorophenyl)amino)-5-methyl-4-pyrimidinyl)-N-((1S)-1-(3-chlorophenyl)-2-hydroxyethyl)-; 4-(2-((2-Chloro-4-fluorophenyl)amino)-5-methyl-4-pyrimidinyl)-N-((1S)-1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide

Networked: 6 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - Vx-11e: 6
  - Pyrimidines: 510
    - Vx-11e: 6

Experts

1.	Jasek-Gajda, Ewa: 2 articles (09/2020 - 12/2019)
2.	Jurkowska, Halina: 2 articles (09/2020 - 12/2019)
3.	Lis, Grzegorz J: 2 articles (09/2020 - 12/2019)
4.	Litwin, Jan A: 2 articles (09/2020 - 12/2019)
5.	Buzdin, Anton A: 1 article (01/2022)
6.	Gong, Yuhang: 1 article (01/2022)
7.	Hong, Zhenghua: 1 article (01/2022)
8.	Ivanenko, Karina A: 1 article (01/2022)
9.	Jiang, Ting: 1 article (01/2022)
10.	Khabusheva, Elmira R: 1 article (01/2022)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 07/05/2021 - "We found that VX-11e, CZC24832, LY2109761, oxaliplatin and erlotinib were effective in inhibiting breast cancer cell lines with high WHSC1L1 expression. "
2.	Leukemia 12/01/2019 - "The aim of this study was to investigate the effect of the combination of ERK2 inhibitor VX-11e and voreloxin on MOLM-14, K562, REH and MOLT-4 leukemia cell lines. " 12/01/2019 - "In conclusion, combination of VX-11e and voreloxin can exert a synergistic anticancer effect in leukemia cells." 12/01/2019 - "The results showed that incubation with both VX-11e and voreloxin inhibited the growth of leukemia cells, affected cell cycle and induced apoptosis. " 12/01/2019 - "Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells." 01/01/2022 - "Using ERK1/2 and downstream kinase ELK1 reporter cell lines of lung cancer (H1299; NRASQ61K), colon cancer (HCT-116; KRASG13D), neuroblastoma (SH-SY5Y), and leukemia (U937), we examined the relationship between ERK inhibition and drug-induced toxicity for five ERK inhibitors: SCH772984, ravoxertinib, LY3214996, ulixertinib, and VX-11e, as well as one MEK inhibitor, PD0325901. "
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/01/2020 - "This study aimed to assess the effect of the combination of ERK2 inhibitor VX-11e and STAT3 inhibitor STA-21 on acute lymphoblastic leukemia cell lines REH and MOLT-4. "
4.	Osteolysis 01/01/2019 - "Low doses of Vx-11e mildly reduced osteoclast resorption whilst no calvarial osteolysis was observed with high dose Vx-11e treatment. " 01/01/2019 - "Through this study, we discovered that the specific and potent ERK1/2 inhibitor, Vx-11e, can protect against calvarial osteolysis caused by titanium (Ti) particles in vivo. " 01/01/2019 - "Collectively, our data provides evidence for the potential therapeutic use of Vx-11e for the treatment of osteolysis diseases caused by extremely actived osteoclastogenesis." 01/01/2019 - "Vx-11e protects against titanium-particle-induced osteolysis and osteoclastogenesis by supressing ERK activity."
5.	Osteoarthritis 01/01/2022 - "VX-11e protects articular cartilage and subchondral bone in osteoarthritis by inhibiting the RIP1/RIP3/MLKL and MAPK signaling pathways."

Related Drugs and Biologics

1.	Oxaliplatin (Eloxatin)
2.	Erlotinib Hydrochloride (CP 358,774)
3.	LY2109761
4.	Titanium
5.	STA-21
6.	vosaroxin
7.	Therapeutic Uses
8.	Mitogen-Activated Protein Kinase Kinases (MEKs)
9.	Phosphotransferases (Kinase)
10.	SCH772984